Bunion

As per the results, patients showed early return to weight bearing in a walking boot at an average of 8.4 days along with low radiographic recurrence rates and reduction in pain Treace Medical Concepts has reported positive three-year results for Lapiplasty procedure. (Credit: Nino Liverani on Unsplash) Treace Medical Concepts has released three-year interim clinical results from its ALIGN3D post-market trial as per which the Lapiplasty 3D Bunion Correction procedure delivered sustained, positive outcomes during bunion treatment. The prospective, five-year, multicentre ALIGN3D study recruited 173 patients who were assessed following the Lapiplasty procedure for surgical management of symptomatic hallux valgus. The primary effectiveness endpoint was defined as radiographic recurrence of the hallux valgus deformity at 24 months follow-up. According to the findings, the patients showed an early return to weight bearing in a walking boot at an average of 8.4 days. The radiographic recurrence rates were low during the latest visit of 0.9% using HVA>20° and 5.2% using HVA>15°. The three-year data also revealed an 81% reduction in pain measured using the Visual Analog Scale (VAS) at 24 months. Additionally, there was an 86% improvement in walking/standing and an 85% improvement in social interaction patient-reported quality of life measures. Furthermore, there were major improvements in patient-reported outcomes across all Patient-Reported Outcomes Measurement Information System domains over time through the latest subject visit. Treace Medical Concepts CEO, founder, and board member John Treace said: “We are pleased that this three-year data from our prospective, multicentre ALIGN3D study continues to demonstrate sustained, successful patient outcomes from our proprietary Lapiplasty Procedure. “We believe these three-year clinical study results set a high standard for a commercial bunion technology and one that further differentiates Lapiplasty in the marketplace with our surgeons and their patients. “We look forward to continuing to expand our market-leading body of clinical evidence, as we advance the standard of care for bunion surgery.” Based in the US, Treace Medical Concepts is focused on advancing the surgical management of bunion and associated midfoot deformities using its flagship Lapiplasty and Adductoplasty procedures. The Lapiplasty 3D Bunion Correction system is designed to surgically correct all three planes of the bunion deformity and secure the unstable joint. It is a combination of instruments, implants, and surgical methods to address the root cause of the bunion and support patients in regaining their active lifestyles.

PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, beginning at approximately 3:45 pm Pacific Time. A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at . Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at . The company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and address the root cause of the bunion, helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible correction of midfoot deformities, as well as its PEEK Hammertoe arthrodesis system, to further support the needs of bunion patients. The company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit . To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook and Instagram. Contacts: Treace Medical Concepts Julie Dewey, IRC Chief Communications & Investor Relations Officer jddewey@treace.com | 209-613-6945

WEST CHESTER, Penn. – October 11, 2023 – Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TriLEAP™ Lower Extremity Anatomic Plating System, a comprehensive yet modular, procedure-specific system designed to meet the complex needs of orthopaedic surgeons, doctors of podiatric medicine, and foot and ankle specialists. The TriLEAP™ System provides a diverse offering of contoured and conventional plates that can accommodate multiple screw diameters, and instruments that can be used during the reduction, internal fixation and fusion of bones and bone fragments.Elective foot surgeries for conditions like bunions are among the fast-growing segments of extremities procedures in orthopaedics and podiatry. In the U.S., one in four people suffer from bunions, or hallux valgus, a progressive disorder of the foot in which deformity gradually increases and can eventually compromise desired lifestyle or mobility.1 Foot and ankle plating systems are implants that are used for bunionectomies, osteotomies, fusions and fractures of the foot or ankle. The systems are attached by surgeons to the affected area and are designed to stabilize the bones.The TriLEAP™ Lower Extremity Anatomic Plating System offers multiple procedure-specific plate options to cover a wide range of procedures, as well as an extensive procedure‐specific implant choice with multiple screw shaft diameters that provide surgeons with various options for intraoperative decisions.“As a leader in elective foot and ankle procedures, DePuy Synthes is dedicated to developing novel solutions tailored to the changing needs of both patients and surgeons,” said Oray Boston***, Worldwide President, DePuy Synthes Trauma, Extremities, Craniomaxillofacial, Animal Health and Sports. “The development and clearance of the TriLEAP™ Lower Extremity Anatomic Plating System is a prime example of how we are maintaining our speed of innovation in the space to address unmet needs and help achieve the best possible outcomes for patients.”DePuy Synthes expects the TriLEAP™ Lower Extremity Anatomic Plating System to be available in the U.S. in 2024. For more information on the TriLEAP™ System and otherDePuy Synthes Foot & Ankle specialty products, read more here.About Johnson & Johnson MedTechAt Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more information, visit https://thenext.jnjmedtech.com/.About DePuy SynthesDePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to healthcare systems worldwide. Building on our proud product innovation and legacy of industry firsts, we are reimagining the orthopaedic landscape with new advancements in medical technologies and digital surgery across the entire continuum of care to Keep People Moving today and tomorrow. For more information, visit www.depuysynthes.com.Cautions Concerning Forward-Looking StatementsThis press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the TriLEAP™ Lower Extremity Anatomic Plating System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, Inc., Medical Device Business Services, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of eitherDePuy Synthes, Inc., Medical Device Business Services, Inc., nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.* Comprising the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson’s MedTech segment.** DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.***Oray Boston is an employee of Medical Device Business Services, Inc.Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.259598-231005 DSUS© DePuy Synthes 2023. All rights reserved.References1Roddy E, Weiya Z, Doherty M. Prevalence and associations of hallux valgus in a primary care population. Arthritis Care & Research 2008 59(6):857-862